Full Press Release Details
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS).
ZYME
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
Key Takeaway: Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
Price reaction · baseline $7.76 (2022-11-18 close) · clean, no other ZYME news in the window
day 0 close · peak
+2.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers